Factors Affecting Canagliflozin-Induced Transient Urine Volume Increase in Patients with Type 2 Diabetes Mellitus

Advances in Therapy

Volumn 34, Issue 2, 2017, Pages 436-451

  Tanaka, Hiroyuki ^a   Takano, Kazuhiko ^b   Iijima, Hiroaki ^a   Kubo, Hajime ^a   Maruyama, Nobuko ^a   Hashimoto, Toshio ^a   Arakawa, Kenji ^a   Togo, Masanori ^a   Inagaki, Nobuya ^c   Kaku, Kohei ^d  

^a MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

^b Medical Corporation Hokubu Kai Utsukushigaoka Hospital   (Japan)

^c KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Canagliflozin; Diuresis; Natriuresis; Sodium glucose co transporter 2; Type 2 diabetes mellitus

Indexed keywords

ALDOSTERONE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ATRIAL NATRIURETIC FACTOR; CANAGLIFLOZIN; CREATININE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INSULIN; KETONE BODY; ORAL ANTIDIABETIC AGENT; POTASSIUM; RENIN; SODIUM; VASOPRESSIN; ANTIDIABETIC AGENT; BRAIN NATRIURETIC PEPTIDE; GLUCOSE BLOOD LEVEL; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76); SODIUM GLUCOSE COTRANSPORTER 2;

ADULT; ALDOSTERONE BLOOD LEVEL; ANOREXIA; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; CORRELATIONAL STUDY; CREATININE BLOOD LEVEL; DIABETIC PATIENT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EXPLORATORY RESEARCH; FEMALE; FLUID INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE URINE LEVEL; GLUCOSURIA; HEMATOCRIT; HORMONE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; JAPANESE (PEOPLE); KALIURESIS; MALAISE; MALE; MEAL; MIDDLE AGED; NATRIURESIS; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; NORMAL VALUE; OSMOTIC DIURESIS; PLASMA RENIN ACTIVITY; POTASSIUM EXCRETION; PROTEIN BLOOD LEVEL; REPEATED DRUG DOSE; SERUM OSMOLALITY; SIDE EFFECT; SODIUM EXCRETION; SODIUM RETENTION; SODIUM URINE LEVEL; UREA NITROGEN BLOOD LEVEL; URINARY EXCRETION; URINE OSMOLALITY; URINE VOLUME; VASOPRESSIN BLOOD LEVEL; ANALYSIS; ANTAGONISTS AND INHIBITORS; BLOOD; CHEMICALLY INDUCED; DEHYDRATION; DIABETES MELLITUS, TYPE 2; GLYCOSURIA; JAPAN; METABOLISM; TREATMENT OUTCOME; URINE;

ADULT; BLOOD GLUCOSE; CANAGLIFLOZIN; DEHYDRATION; DIABETES MELLITUS, TYPE 2; FEMALE; GLYCOSURIA; HUMANS; HYPOGLYCEMIC AGENTS; JAPAN; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; SODIUM-GLUCOSE TRANSPORTER 2; TREATMENT OUTCOME;

EID: 85006165373     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-016-0457-8     Document Type: Article

References (32)

1. Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet. 2014;383(9922):1068–83.
2. Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med. 2010;27(2):136–42.
3. DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab. 2012;14(1):5–14.
4. Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol. 2012;8(8):495–502.
5. Mudaliar S, Polidori D, Zambrowicz B, Henry RR. Sodium-glucose cotransporter inhibitors: effects on renal and intestinal glucose transport: from bench to bedside. Diabetes Care. 2015;38(12):2344–53.
6. Lorber D. Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus. Diabetes, Metab Syndr Obes. 2014;7:169–83.
7. Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015;75(1):33–59.
8. Fujita Y, Inagaki N. Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: clinical data and mechanism of action. J Diabetes Investig. 2014;5(3):265–75.
9. Shyangdan DS, Uthman OA, Waugh N. SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. BMJ Open. 2016;6(2):e009417.
10. Ghosh RK, Bandyopadhyay D, Hajra A, Biswas M, Gupta A. Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: a comprehensive review of clinical and preclinical studies. Int J Cardiol. 2016;1(212):29–36.
11. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.
12. Fitchett D, Zinman B, Wanner C, Lachin JM, Hantel S, Salsali A, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(R) trial. Eur Heart J. 2016;37(19):1526–34.
13. Perseghin G, Solini A. The EMPA-REG outcome study: critical appraisal and potential clinical implications. Cardiovasc Diabetol. 2016;15(1):85.
14. Lam KS, Chow CC, Tan KC, Ma RC, Kong AP, Tong PC, et al. Practical considerations for the use of sodium-glucose co-transporter type 2 inhibitors in treating hyperglycemia in type 2 diabetes. Curr Med Res Opin. 2016;32(6):1097–108.
15. Sinclair AJ, Bode B, Harris S, Vijapurkar U, Shaw W, Desai M, et al. Efficacy and safety of canagliflozin in individuals aged 75 and older with type 2 diabetes mellitus: a pooled analysis. J Am Geriatr Soc. 2016;64(3):543–52.
16. Plosker GL. Canagliflozin: a review of its use in patients with type 2 diabetes mellitus. Drugs. 2014;74(7):807–24.
17. Rosenthal N, Meininger G, Ways K, Polidori D, Desai M, Qiu R, et al. Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus. Ann N Y Acad Sci. 2015;1358:28–43.
18. Seufert J. SGLT2 inhibitors—an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin. Diabetes Metab Syndr Obes. 2015;8:543–54.
19. Iijima H, Kifuji T, Maruyama N, Inagaki N. Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus. Adv Ther. 2015;32(8):768–82.
20. Sha S, Devineni D, Ghosh A, Polidori D, Hompesch M, Arnolds S, et al. Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes. PLoS One. 2014;9(9):e110069.
21. Sasaki T, Seino Y, Fukatsu A, Ubukata M, Sakai S, Samukawa Y. Pharmacokinetics, pharmacodynamics, and safety of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a randomized, single-blind, placebo-controlled trial. Adv Ther. 2015;32(4):319–40.
22. Heise T, Seewaldt-Becker E, Macha S, Hantel S, Pinnetti S, Seman L, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks’ treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes Obes Metab. 2013;15(7):613–21.
23. Weinstein AM. A mathematical model of the rat nephron: glucose transport. Am J Physiol Renal Physiol. 2015;308(10):F1098–118.
24. Takeuchi T, Dohi K, Omori T, Moriwaki K, Sato Y, Nakamori S, et al. Diuretic effects of sodium-glucose cotransporter 2 inhibitor in patients with type 2 diabetes mellitus and heart failure. Int J Cardiol. 2015;15(201):1–3.
25. Rennke H, Denker B. Renal pathophysiology: the essentials. 4th ed. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins; 2014.
26. Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013;15(9):853–62.
27. Piuhola J, Kerkela R, Keenan JI, Hampton MB, Richards AM, Pemberton CJ. Direct cardiac actions of erythropoietin (EPO): effects on cardiac contractility, BNP secretion and ischaemia/reperfusion injury. Clin Sci (Lond). 2008;114(4):293–304.
28. Polidori D, Sha S, Mudaliar S, Ciaraldi TP, Ghosh A, Vaccaro N, et al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care. 2013;36(8):2154–61.
29. Kinoshita S, Kondo K. Evaluation of pharmacokinetic and pharmacodynamic interactions of canagliflozin and teneligliptin in Japanese healthy male volunteers. Expert Opin Drug Metab Toxicol. 2015;11(1):7–14.
30. Grempler R, Thomas L, Eckhardt M, Himmelsbach F, Sauer A, Sharp DE, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab. 2012;14(1):83–90.
31. Oguma T, Nakayama K, Kuriyama C, Matsushita Y, Yoshida K, Hikida K, et al. Intestinal sodium glucose cotransporter 1 inhibition enhances glucagon-like peptide-1 secretion in normal and diabetic rodents. J Pharmacol Exp Ther. 2015;354(3):279–89.
32. Inagaki N, Goda M, Yokota S, Maruyama N, Iijima H. Safety and efficacy of canagliflozin in Japanese patients with type 2 diabetes mellitus: post hoc subgroup analyses according to body mass index in a 52-week open-label study. Expert Opin Pharmacother. 2015;16(11):1577–91.